Combination of microtubule targeting agents with other antineoplastics for cancer treatment
Tingting Liang1, Lu Lu1, Xueting Song1
1Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng, Henan Province 475004, China.
Abstract:
Microtubule targeting agents (MTAs) have attracted extensive attention for cancer treatment. However, their clinical efficacies are limited by intolerable toxicities, inadequate efficacy and acquired multidrug resistance. The combination of MTAs with other antineoplastics has become an efficient strategy to lower the toxicities, overcome resistance and improve the efficacies for cancer treatment. In this article, we review the combinations of MTAs with some other anticancer drugs, such as cytotoxic agents, kinases inhibitors, histone deacetylase inhibitors, immune checkpoints inhibitors, to overcome these obstacles. We strongly believe that this review will provide helpful information for combination therapy based on MTAs.
Insights
Combining microtubule targeting agents (MTAs) with other anticancer drugs can overcome resistance and reduce toxicity. This review explores MTA combinations for improved cancer treatment efficacy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Microtubule targeting agents (MTAs) are crucial in cancer therapy.
- Clinical use of MTAs is hindered by toxicity, resistance, and limited efficacy.
Purpose of the Study:
- To review combination strategies involving MTAs and other anticancer agents.
- To highlight methods for overcoming MTA-related challenges in cancer treatment.
Main Methods:
- Literature review of MTA combinations with various antineoplastics.
- Analysis of combinations with cytotoxic agents, kinase inhibitors, HDAC inhibitors, and immune checkpoint inhibitors.
Main Results:
- Combination therapy can mitigate MTA toxicity and overcome multidrug resistance.
- Synergistic effects observed in combining MTAs with diverse anticancer drug classes.
Conclusions:
- Combining MTAs with other anticancer drugs offers a promising strategy to enhance cancer treatment outcomes.
- This review provides valuable insights for developing effective MTA-based combination therapies.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
06:02Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Related Concept Videos
Drugs that Stabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
